2024-05-20 13:02:41 ET
Summary
- Cellectar Biosciences, Inc. is focused on developing a radiopharmaceutical for Waldenstrom's macroglobulinemia, a type of non-Hodgkin lymphoma.
- The company has positive topline data from a pivotal study, with a high response rate in patients with Waldenstrom's macroglobulinemia.
- Cellectar Biosciences has a strong pipeline and potential for commercialization, but cash concerns and the timeline for approval are risks.
Topline Summary and Update
Read the full article on Seeking Alpha
For further details see:
Cellectar Biosciences: Still Working On That Hit (Maintain Buy)